UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2277-4
Program Prior Authorization/Medical Necessity
Medication Pyrukynd® (mitapivat)
P&T Approval Date 5/2022, 5/2023, 5/2024, 5/5025
Effective Date 8/1/2025
1. Background:
Pyrukynd® (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic
anemia in adults with pyruvate kinase (PK) deficiency.
2. Coverage Criteriaa:
A. Initial Authorization
1. Pyrukynd will be approved based on all of the following criteria:
a. Diagnosis of pyruvate kinase (PK) deficiency based on all of the following:
(1) Presence of at least 2 variant alleles in the pyruvate kinase liver and red blood
cell (PKLR) gene, of which at least 1 is a missense variant
-AND-
(2) Patient is not homozygous for the c.1436G>A (p.R479H) variant
-AND-
(3) Patient does not have 2 non-missense variants (without the presence of
another missense variant) in the PKLR gene
-AND-
b. Used for the treatment of hemolytic anemia
-AND-
c. One of the following:
(1) Both of the following:
i. Baseline hemoglobin less than or equal to 10 g/dL
-AND-
ii. Patient has had no more than 4 transfusions in the previous 52 weeks and
no transfusions in the preceding 3-month period
© 2025 UnitedHealthcare Services, Inc.
1
-OR-
(2) Patient has had a minimum of 6 transfusion episodes in the preceding 52
weeks
-AND-
d. Prescribed by a nephrologist or hematologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Pyrukynd will be approved based on one of the following criteria:
(1) Both of the following:
i. Documentation of positive clinical response to Pyrukynd therapy
-AND-
ii. Prescribed by, or in consultation with, a nephrologist or hematologist
Authorization will be issued for 12 months.
-OR-
(2) Documentation does not provide evidence of positive clinical response to
Pyrukynd therapy, allow for dose titration with discontinuation of therapy
Authorization will be issued for 4 weeks.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Pyrukynd [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc.; January 2025.
© 2025 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Medical Necessity – Pyrukynd® (mitapivat)
Change Control
5/2022 New program.
5/2023 Annual review. No changes.
5/2024 Updated initial approval duration from 6 months to 12 months.
Simplified reauthorization criteria.
5/2025 Annual review. No changes to clinical criteria.
© 2025 UnitedHealthcare Services, Inc.
3